Featured Lymphoma Content
Oncologist Michelle Fanale, MD, and oncology nurse Rinata Simien, RN, NP-C, discuss the clinical treatment options for patients with relapsed Hodgkin lymphoma and anaplastic large cell lymphoma.
Lymphoma News and Features
Nivolumab Improves Clinical Outcomes in Patients With Relapsed-Refractory Hodgkin Lymphoma After ASCT, Brentuximab Vedotin
Study reports that patients with classic relapsed/refractory Hodgkin lymphoma who received nivolumab after ASCT experienced high rates of response regardless of previous history with brentuximab vedotin.
Rituximab in the Treatment of Follicular Lymphoma: the Future of Biosimilars in the Evolving Therapeutic Landscape
[Cancer Management and Research] This research summarizes the role of rituximab across the spectrum of FL treatment and the evolving therapeutic landscape with the emergence of novel agents currently in clinical development.
Hodgkin lymphoma survivors are at higher risk of second cancers, and that risk is even higher in those with a first-degree relative with cancer.
Patients who were surveyed reported that the benefits of treatment with BV outweighed its risks.
PD-1 blockade with pembrolizumab was active and induced durable responses in patients with natural killer (NK)/T-cell lymphoma failing L-asparaginase.
[OncoTargets and Therapy] This research examines the efficacy and safety of recombinant human endostatin in combination with CHOP regimen (ECHOP) for patients with peripheral T cell lymphoma.
Researchers sought to compare the efficacy of O-DHAP with R-DHAP as salvage treatment, followed by autologous hematopoietic cell transplantation.
The patient's history and current blood work results indicated a dangerously high potassium level. But a meticulously handled redraw proved it false.
Frontline treatment with rituximab plus high-dose sequential chemotherapy with autologous HSCT failed to improve progression-free or overall survival compared with R-CHOP in patients with diffuse large B-cell lymphoma.
Severe fatigue is associated with unemployment and financial problems in survivors of Hodgkin lymphoma, highlighting the need for clinicians to address fatigue in these patients.
Peripheral T-cell lymphoma (PTCL) is a rare and aggressive form of cancer. This fact sheet explains the condition to newly diagnosed patients and provides sources of support.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Coping With Lymphedema: A Patient Guide (Fact Sheet)
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|